Study of the efficacy, safety and tolerability of Abexol (suspension) versus Abexol (tablets) in patients with gastrointestinal symptoms - ASATSG

ational Centre for Scientific Research0 个研究点目标入组 100 人开始时间: 2021年5月22日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: Randomized controlled trial. Masking: Open. Control group: Active. Assignment: Parallel. Purpose: Treatment

•Patients with non-erosive erythomatous gastritis, both sexes, aged between 19 and 70 years, with gastrointestinal symptoms such as: epigastralgia (abdominal pain localized in the epigastric region), heartburn, nausea, heartburn, flatulence, regurgitation, belching, abdominal distension, feeling of rapid satiety, vomiting, anorexia incomplete, emptying sensation, attend an outpatient consultation at the Institute of Gastroenterology and agree to participate in the study by signing the informed consent.

•Patients with
•Confirmatory endoscopy of gastric, duodenal or esophageal ulcer.
•Organic lesions of the upper digestive tract that require specific treatment.
•Benign and malignant digestive neoplasms.
•Alarm symptoms (digestive bleeding, anemia, significant loss of body weight, progressive dysphagia, odynophagia, persistent vomiting, lymphadenopathy, palpation of abdominal mass).
•Active liver or kidney diseases.
•Other non-digestive neoplasms.
•Thyroid gland disorders.
•Irritable bowel syndrome.
•Pancreatic conditions (acute or acute chronic pancreatitis).
•Intra and extrahepatic bile duct disorders.
•Izchemic alterations.
•Glucose > 7 mmol / L, and ALT> 55 IU, and / or creatinine> 130 umol / L.
•Diastolic blood > 105 mm Hg.
•Patients with any other special condition that at the discretion of the doctor puts their health and life at risk during the study.

发起方

ational Centre for Scientific Research